Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07738315

Elemene Liposomes in Endometrial Cancer

The goal of this clinical trial is to learn if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer. The main question it aims to answer is:

Does adding Elemene Liposomes to TC chemotherapy can delay disease recurrence time in patients with advanced or recurrent endometrial carcinoma.

Researchers will compare Elemene Liposomes +TC chemotherapy to TC chemotherapy alone to see if Elemene Liposomes, combined with carboplatin and paclitaxel (TC) chemotherapy can improve prognosis in patients with advanced or recurrent endometrial cancer.

Participants will:

* Receive TC Chemotherapy every 21 days, for a total of 6 cycles. * Take intravenous infusion of Elemene liposome injection every day from day 1 to day 7 of cycle 1 and 2, and take oral Elemene emulsion twice every day, from day 1 to day 14 of cycles 3 to cycle 6. (no intravenous or oral Elemene will be given in comparison group) * Visit the clinic for checkups and tests once every 21 days during treatment and every 3 to 12 months after the treatment is completed.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Endometrial Carcinoma Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

18 year–80 year

Sex eligibility

Female

Study type

Interventional

Phase

Phase 2

Primary location

Women's hospital School of Medicine Zhejiang University

Hangzhou, Zhejiang, 310000, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Histopathologically confirmed endometrial malignancy via surgery or biopsy, including endometrioid carcinoma, serous adenocarcinoma, clear cell carcinoma, mixed epithelial carcinoma, dedifferentiated/undifferentiated carcinoma, carcinosarcoma, etc. Non-epithelial tumors such as mesenchymal tumors, neuroectodermal tumors and germ cell tumors are excluded.
  • Treatment-naïve patients with FIGO 2009 stage III-IV disease, or patients with clinically diagnosed recurrent endometrial malignancy (no restriction on the number of recurrences, and no restriction on whether reoperation was performed after recurrence). Patients must not have received chemotherapy, anti-tumor immunotherapy or radiotherapy within 6 months before randomization.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days prior to randomization.
  • Adequate organ function defined as: white blood cell count ≥3.5×10⁹/L, absolute neutrophil count ≥1.5×10⁹/L, platelet count ≥80×10⁹/L, serum total bilirubin ≤1.5×upper limit of normal (ULN), transaminases (alanine aminotransferase, aspartate aminotransferase) ≤1.5×ULN, serum creatinine and blood urea nitrogen ≤1.5×ULN OR calculated creatinine clearance ≥30 mL/min. All laboratory tests shall be performed within 7 days prior to randomization. Left ventricular ejection fraction ≥lower limit of normal (50%) as assessed by Doppler echocardiography.
  • Negative serum or urine pregnancy test within 7 days before enrollment, and non-lactating status.

Exclusion criteria

  • History of other primary malignant tumors within 3 years prior to randomization.
  • Concurrent participation in another clinical study, except for observational, non-interventional clinical studies.
  • Uncontrolled concomitant diseases, including but not limited to cardiac disorders, cerebral diseases, hematological diseases, congenital or postoperative hepatic/renal abnormalities; drug and/or alcohol abuse.
  • Severe postoperative complications that have not fully resolved.
  • Known allergy or contraindications to the study drugs (Elemene Liposomes Injection, Elemene Emulsion Oral Solution).

Treatment and study plan

Elemene Injection/Elemene Oral Emulsion

Drug

21 day cycle: Elemene Liposomes intravenous infusion 528 mg once daily from day 1 to day 7 for the first 2 cycles, Elemene Emulsion 176 mg orally twice daily from day 1 to day 14 for cycle 3 to cycle 6.

Other names: Elemene

Carboplatin-Paclitaxel chemotherapy

Drug

21 day cycle: Paclitaxel 175 mg/m² intravenous infusion on day 1 for 6 cycles, Carboplatin AUC=5 intravenous infusion on day 1 for 6 cycles

Other names: TC

Primary outcomes

  1. Progression-Free Survival Rate at 24 Months as Assessed by RECIST v1.1

    Time frame: 24 months from randomization

    The probability that a patient remains free of documented disease progression (per RECIST 1.1 ) or death from any cause at 24 months after randomization estimated via the Kaplan-Meier method.

Secondary outcomes

  1. Overall Survival Rate at 24 Months

    Time frame: 24 months from randomization

    Defined as the probability that patients remain alive at 24 months from randomization estimated via the Kaplan-Meier method. Death from any cause is counted as the endpoint event.

  2. Remission rate (%) as Assessed by RECIST 1.1 Criteria

    Time frame: From randomization to the end of treatment at 18 weeks.

    The proportion of patients achieving a confirmed complete response (CR) or partial response (PR) according to RECIST 1.1 criteria. Only patients with measurable disease at baseline are included in the evaluable population for ORR.

  3. Adverse Event

    Time frame: From initiation of treatment until the end of the 5-year follow-up period.

    Adverse Effects of antitumor therapy

  4. Patient-Reported Outcome as Assessed by European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30

    Time frame: From randomization to the end of treatment at 18 weeks.

    Health information directly reported by patients reflecting health-related quality of life. measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30).

  5. Patient-reported outcome as Assessed by EQ-5D-5L

    Time frame: From randomization to the end of treatment at 18 weeks.

    Health information directly reported by patients, reflecting symptoms, function and health-related quality of life as Assessed by EuroQol Five-Dimensional Five-Level Questionnaire (EQ-5D-5L).

Study contacts

Contact information is provided by the study sponsor or research team.

Yang Li

CONTACT

[email protected]

0086-0571-87061501

Sponsors and collaborators

Lead sponsor

Women's Hospital School Of Medicine Zhejiang University

Other

Collaborators

  • Beijing Friendship Hospital
  • Fujian Maternity and Child Health Hospital
  • Jiangxi Maternal and Child Health Hospital
  • Jiaxing Maternity and Child Health Care Hospital
  • Ningbo Women & Children's Hospital
  • Second Affiliated Hospital of Wenzhou Medical University
  • Second Affiliated Hospital, School of Medicine, Zhejiang University
  • The First Affiliated Hospital of Zhengzhou University

Registry information

Official study title

A Prospective, Multicenter, Randomized Controlled Trial of Elemene Liposomes Combined With TC Chemotherapy in Advanced or Recurrent Endometrial Cancer

Important dates

Study start
2026
Primary completion
2031
Study completion
2031
First posted
Jul 31, 2026
Registry last updated
Jul 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.